Capital Group, the parent of American Funds, recently completed its latest periodic firmwide self-assessment, which will result in personnel changes across its fund lineup, including American Funds ...

Capital Group, the parent of American Funds, recently completed its latest periodic firmwide self-assessment, which will result in personnel changes across its strategy lineup, including American ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Ed Whelan holds the Antonin Scalia Chair in Constitutional Studies at the Ethics and Public Policy Center. A regular contributor to National Review’s blog Bench Memos, he has closely covered every ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining traction among investors, buoyed by promising clinical data and potential regulatory advancements. Recent market sentiment also improved due to ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.